Lilly Will Invest Additional $5.3B In Indiana Pharmaceutical Manufacturing

New investment brings Lilly’s total commitment at LEAP Research and Innovation District in Lebanon to $9 billion, 900 new jobs.  

Eli Lilly and Company plans to more than double its investment at the LEAP Research and Innovation District in Lebanon, Indiana. The added investment will enhance the company’s capacity to manufacture active pharmaceutical ingredients (API) for its latest type 2 diabetes and obesity medicines. The announcement was made today during the Indiana Global Economic Summit. The new $5.3 billion expansion brings Lilly’s total LEAP investment to $9 billion.

In addition to the new investment, Lilly will create another 200 jobs for highly skilled workers, such as engineers, scientists, operating personnel and lab technicians. The new positions will bring the company’s total planned new jobs at LEAP to 900.

Lilly Indiana
Governor Eric Holcomb joined Eli Lilly and Company Chair and CEO Dave Ricks at the Indiana Global Economic Summit to announce Lilly’s plans to more than double its investment at the LEAP Research and Innovation District in Lebanon. The new expansion will enhance Lilly’s capacity to manufacture pharmaceutical ingredients for current and future medicines to fight type 2 diabetes and obesity. (Photo: IEDC)


“Today’s announcement tops the largest manufacturing investment in our company’s history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history,” said Lilly Chair and CEO David A. Ricks. “This multi-site campus will make our latest medicines, support pipeline growth and leverage the latest technology and automation for maximum efficiency, safety and quality control. Importantly, we are investing in our home state of Indiana, creating high-wage, advanced manufacturing, engineering and science jobs for hundreds of current and future Hoosier families.”

“Today’s announcement tops the largest manufacturing investment in our company’s history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history.”

— David A. Ricks, Chair and CEO, Eli Lilly and Company 

Since 2020, Lilly has committed more than $16 billion to develop new manufacturing sites in the U.S. and Europe. New locations outside of Indiana include Research Triangle Park and Concord, NC; Limerick, Ireland; and Alzey, Germany. Separately, Lilly has invested an additional $1.2 billion to update existing manufacturing facilities in Indianapolis.

In May 2022, Lilly first announced its plans to invest $2.1 billion and create up to 500 new jobs at LEAP. At the company’s Lebanon groundbreaking in April 2023, Lilly announced an additional $1.6 billion investment and 200 new jobs at the site. Since breaking ground at LEAP, Lilly has transformed a significant portion of its 600 acres at the site into an active construction site and expects to begin making medicines there in late 2026.

Based on the company’s plans to create 200 additional new jobs at LEAP, the Indiana Economic Development Corporation (IEDC) committed an additional investment in Lilly of up to $500,000 in the form of incentive-based training grants. The IEDC also committed an additional investment of up to $20 million in redevelopment tax credits and $15 million in road infrastructure improvements based on the company’s announced plans to invest an additional $5.2 billion.

Furthermore, with a total estimated capital investment of $9.7 billion and the hiring of 900 high-wage positions by Lilly at their LEAP site, the IEDC revised its Innovation Development District award structure to accommodate a 30-year benefit period with an estimated value of $1.2 billion in tax rebates and the flexibility for the project to further grow. All incentives remain subject to final IEDC Board of Directors and state of Indiana required approvals and contracting.

Indiana will also help develop a robust workforce ecosystem of qualified manufacturing talent by providing the land and helping to raise capital for a new workforce training center that will be part of the larger LEAP industrial development. The new training center will have added impact by aligning with Lilly’s previously announced financial support for scholarship and training programs with Purdue University and Ivy Tech Community College, as well as the BioCrossroads-led training center at 16 Tech — part of Indiana’s recent Tech Hub designation.

AWS IndianaAmazon Makes Largest Investment Announcement In Indiana History

Amazon Web Services (AWS) will invest $11B to create a new data center campus in Northern Indiana. Toyota will invest $1.4B in SW Indiana. Read more…

“Lilly continues to play a transformational role in shaping Indiana’s opportunity economy, and I couldn’t be more proud about their pole position leadership in developing the LEAP Research and Innovation District in Lebanon, Indiana,” said Governor Eric J. Holcomb. “Lilly has long been driving global innovation and economic growth that will be felt for decades here at home.”

“As an international company, headquartered in Indiana, Lilly had a world of options to consider before making this investment, and choosing Indiana once again reinforces the incredible environment we’ve cultivated and the talented workforce we have to carry Lilly’s success forward,” Gov. Holcomb continued. “I can’t wait to see the incredible benefits this investment leads to for patients around the world, knowing they were made in Indiana.”

“We are excited about Eli Lilly and Company’s plan to expand their investment in Lebanon, reinforcing their role as a key community partner in driving future innovation and economic prosperity,” added Lebanon Mayor Matt Gentry. “Their investment underscores our shared commitment to creating greater opportunities and enhancing the quality of life for our residents and community.”

Check out all the latest news related to Indiana economic development, corporate relocation, corporate expansion and site selection.


Please enter your comment!
Please enter your name here